Differential microRNA expression in renal cell carcinoma

Cheng,Tingting; Wang,Lina; Li,Yuyao; Huang,Chen; Zeng,Lingxia; Yang,Jin

doi:10.3892/ol.2013.1460

Differential microRNA expression in renal cell carcinoma

Authors:
- Tingting Cheng
- Lina Wang
- Yuyao Li
- Chen Huang
- Lingxia Zeng
- Jin Yang
View Affiliations

Affiliations: Department of Medical Oncology, First Affiliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Genetics and Molecular Biology, Medical School, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Statistics, Medical School, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: July 12, 2013 https://doi.org/10.3892/ol.2013.1460
Pages: 769-776

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to detect microRNA expression levels in the tissues and sera of patients with clear cell renal cell carcinoma (ccRCC). The association of microRNA expression with ccRCC clinical pathology was analyzed, and the potential of the microRNAs as ccRCC serum markers and the significance of their expression in the clinical diagnosis, staging, prognosis and selection of new therapeutic targets for ccRCC were discussed. Specific microRNAs were selected according to the associated literature. TaqMan quantitative polymerase chain reaction (qPCR) technology was used to determine the expression levels of selected microRNAs. miR‑34a, miR‑224 and miR‑21 were upregulated, whereas miR‑141, miR‑149 and miR‑429 were downregulated in the ccRCC tissues (P<0.01). The expression of miR‑221 and miR‑211 was not significant in the ccRCC tissues (P>0.05). miR‑34a, miR‑21 and miR‑224 were upregulated and miR-141 was downregulated in the sera of patients with ccRCC (P<0.01), while the expression of miR‑149 and miR‑429 was not significant (P>0.05). The serum miR‑21 expression levels were significantly correlated with the clinical staging of the patients with ccRCC (P<0.05). miR‑34a, miR‑21 and miR‑224 are upregulated in the tissues and sera of patients with ccRCC, whereas miR‑141 is downregulated. miR‑21 and miR‑141 are associated with ccRCC and are, thus, potential ccRCC serum markers.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar
2	Gottardo F, Liu CG, Ferracin M, et al: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 25:387–392. 2007. View Article : Google Scholar : PubMed/NCBI
3	Escudier B: Advanced renal cell carcinoma: current and emerging management strategies. Drugs. 67:1257–1264. 2007. View Article : Google Scholar : PubMed/NCBI
4	Broghammer EL and Ratliff TL: Immunotherapy of urologic tumors: principles and progress. Urol Oncol. 7:45–56. 2002. View Article : Google Scholar : PubMed/NCBI
5	Mulders P, Figlin R, deKernion JB, et al: Renal cell carcinoma: recent progress and future directions. Cancer Res. 57:5189–5195. 1997.PubMed/NCBI
6	Bukowski RM, Eisen T, Szczylik C, et al: Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. J Clin Oncol. 25:50232007.
7	Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
8	Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 356:2271–2281. 2007. View Article : Google Scholar
9	Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 370:2103–2111. 2007. View Article : Google Scholar
10	Jonasch E, Wood CG, Matin SF, et al: Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 27:4076–4081. 2009. View Article : Google Scholar : PubMed/NCBI
11	Sternberg CN, Davis ID, Mardial J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomised phase III trial. J Clin Oncol. 28:1061–1068. 2010. View Article : Google Scholar : PubMed/NCBI
12	Motzer RJ, Escudier B, Oudard S, et al: Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 116:4256–4265. 2010. View Article : Google Scholar : PubMed/NCBI
13	Walsh PC, Retik AB, Vaugh ED, et al: Campbell’s Urology. 8th edition. WB Saunders Company; Philadelphia, PA: pp. 2672–2719. 2002
14	Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other disease. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
15	Chen ZY: The expression of circulated microRNA in ccRCC (unpublished PhD thesis). Zhongnan University; 2010
16	Nakada C, Matsuura K, Tsukamoto Y, et al: Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol. 216:418–427. 2008. View Article : Google Scholar : PubMed/NCBI
17	Jung M, Mollenkopf HJ, Grimm C, et al: MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med. 13:3918–3928. 2009. View Article : Google Scholar : PubMed/NCBI
18	Li M: MicroRNA expression profiling in renal cell carcinoma and its potential clinical significance (unpublished PhD thesis). Zhongshan University; 2009
19	Huang Y, Dai Y, Yang J, et al: Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur J Surg Oncol. 35:1119–1123. 2009. View Article : Google Scholar : PubMed/NCBI
20	Slaby O, Jancovicov J, Lakomy R, et al: Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res. 29:902010. View Article : Google Scholar : PubMed/NCBI
21	Liu H, Brannon AR, Reddy AR, et al: Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol. 4:512010. View Article : Google Scholar : PubMed/NCBI
22	Juan D, Alexe G, Antes T, et al: Identification of a microRNA panel for clear-cell kidney cancer. Urology. 75:835–841. 2010. View Article : Google Scholar : PubMed/NCBI
23	Chow TF, Youssef YM, Lianidou E, et al: Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem. 43:150–158. 2010. View Article : Google Scholar : PubMed/NCBI
24	Yi Z, Fu Y, Zhao S, Zhang X and Ma C: Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J Cancer Res Clin Oncol. 136:855–862. 2010. View Article : Google Scholar : PubMed/NCBI
25	Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
26	Wei J, Gao W, Zhu CJ, et al: Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer. 30:407–414. 2011. View Article : Google Scholar : PubMed/NCBI
27	Tomimaru Y, Equchi H, Naqano H, et al: Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol. 56:167–175. 2012. View Article : Google Scholar : PubMed/NCBI
28	Nam EJ, Yoon H, Kim SW, et al: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
29	Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ and Ward DC: Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate- specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer. 9:39–45. 2011. View Article : Google Scholar
30	Yaman Agaoglu F, Kovancilar M, Dizdar Y, et al: Investigation of miR-21, miR-141, miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 32:583–588. 2011.PubMed/NCBI
31	Cheng H, Zhang L, Cogdell DE, et al: Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PloS One. 6:e177452011. View Article : Google Scholar : PubMed/NCBI
32	Zaman MS, Shahryari V, Deng G, et al: Up-regulation of microRNA-21 correlates with lower kidney cancer survival. PLoS One. 7:e310602012. View Article : Google Scholar : PubMed/NCBI
33	Boquslawska J, Wojcicka A, Piekielko-Witkowska A, Master A and Nauman A: MiR-224 targets the 3′UTR of type 1 5′-iodothyronine deiodinase possibly contributing to tissue hypothyroidism in renal cancer. PLoS One. 6:e245412011.
34	Gibbons DL, Lin W, Creighton CJ, et al: Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 23:2140–2151. 2009. View Article : Google Scholar : PubMed/NCBI